X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (593) 593
science & technology (577) 577
life sciences & biomedicine (563) 563
diphosphonates - administration & dosage (427) 427
female (425) 425
male (311) 311
bone density conservation agents - administration & dosage (310) 310
infusions, intravenous (303) 303
middle aged (292) 292
aged (285) 285
diphosphonates - adverse effects (283) 283
zoledronic acid (266) 266
diphosphonates - therapeutic use (257) 257
imidazoles - administration & dosage (246) 246
bisphosphonates (230) 230
bone density conservation agents - adverse effects (214) 214
osteoporosis (204) 204
bone density conservation agents - therapeutic use (202) 202
injections, intravenous (182) 182
imidazoles - adverse effects (167) 167
intravenous administration (158) 158
imidazoles - therapeutic use (154) 154
bone neoplasms - secondary (150) 150
treatment outcome (148) 148
bone neoplasms - drug therapy (139) 139
oncology (137) 137
administration, oral (133) 133
endocrinology & metabolism (130) 130
adult (124) 124
bones (124) 124
aged, 80 and over (114) 114
risk factors (111) 111
dentistry (109) 109
medicine & public health (106) 106
bone density - drug effects (102) 102
care and treatment (102) 102
drug administration schedule (102) 102
dentistry, oral surgery & medicine (100) 100
osteoporosis - drug therapy (98) 98
drug therapy (97) 97
orthopedics (93) 93
fractures (91) 91
surgery (88) 88
abridged index medicus (84) 84
phosphonates (81) 81
cancer (78) 78
osteonecrosis - chemically induced (77) 77
breast neoplasms - pathology (76) 76
clinical trials (76) 76
necrosis (76) 76
diphosphonates (75) 75
follow-up studies (75) 75
time factors (75) 75
bisphosphonate (73) 73
osteonecrosis (73) 73
osteoporosis, postmenopausal - drug therapy (73) 73
research (70) 70
retrospective studies (66) 66
breast neoplasms - drug therapy (65) 65
metastasis (65) 65
animals (63) 63
bone density (63) 63
analysis (62) 62
bone mineral density (62) 62
breast cancer (60) 60
patients (60) 60
rheumatology (60) 60
health aspects (59) 59
pharmacology & pharmacy (59) 59
jaw diseases - chemically induced (58) 58
medicine, general & internal (57) 57
general & internal medicine (56) 56
diphosphonates - pharmacology (55) 55
double-blind method (55) 55
administration, intravenous (50) 50
endocrinology (50) 50
dose-response relationship, drug (49) 49
jaw (47) 47
pamidronate (47) 47
prospective studies (47) 47
ibandronate (45) 45
dosage and administration (44) 44
child (42) 42
pain (42) 42
acids (41) 41
imidazoles - pharmacology (41) 41
multiple myeloma - drug therapy (41) 41
postmenopausal women (41) 41
chemotherapy (39) 39
multiple myeloma (39) 39
bone metastases (38) 38
adolescent (37) 37
denosumab (37) 37
prostate cancer (37) 37
bone density conservation agents - pharmacology (35) 35
complications and side effects (35) 35
hip (34) 34
incidence (34) 34
randomized controlled trials as topic (34) 34
density (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (693) 693
Japanese (7) 7
German (6) 6
Chinese (4) 4
Italian (3) 3
Portuguese (3) 3
Dutch (2) 2
French (1) 1
Hungarian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 05/2007, Volume 356, Issue 18, pp. 1809 - 1822
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2007, Volume 357, Issue 18, pp. 1799 - 1809
Journal Article
Journal of bone and mineral research, ISSN 0884-0431, 03/2011, Volume 26, Issue 3, pp. 503 - 511
.... To evaluate the effects of combination therapy with an intravenous infusion of zoledronic acid 5... 
ZOLEDRONIC ACID | INFUSION | TERIPARATIDE | BISPHOSPHONATE | OSTEOPOROSIS | Bisphosphonate | teriparatide | infusion | osteoporosis | zoledronic acid | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Collagen Type I - blood | Peptides - blood | Injections, Intravenous | Teriparatide - therapeutic use | Bone Density - physiology | Follow-Up Studies | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Imidazoles - administration & dosage | Osteoporotic Fractures - drug therapy | Bone Remodeling - physiology | Injections, Subcutaneous | Peptide Fragments - blood | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Osteoporotic Fractures - physiopathology | Diphosphonates - adverse effects | Biomarkers - metabolism | Bone Density Conservation Agents - adverse effects | Teriparatide - administration & dosage | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Procollagen - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Osteoporosis, Postmenopausal - blood | Osteoporotic Fractures - complications | Least-Squares Analysis | Osteoporosis, Postmenopausal - physiopathology | Teriparatide - adverse effects | Aged | Osteoporotic Fractures - blood | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2012, Volume 367, Issue 18, pp. 1714 - 1723
Journal Article
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 1989 - 1999
Summary Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Multiple Myeloma - secondary | Bone Neoplasms - secondary | Imidazoles - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Multiple Myeloma - drug therapy | Diphosphonates - therapeutic use | Adult | Female | Imidazoles - therapeutic use | Odds Ratio | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Bone Density Conservation Agents - therapeutic use | Logistic Models | Treatment Outcome | United Kingdom | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Neoplasms - prevention & control | Clodronic Acid - therapeutic use | Aged | Clodronic Acid - administration & dosage | Infusions, Intravenous | Neoplasm Staging | Research Design | Zoledronic acid | Complications and side effects | Dosage and administration | Drug therapy | Patient outcomes | Multiple myeloma | Medical research | Chemotherapy | Radiation therapy | Medical treatment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Osteoporosis international, ISSN 0937-941X, 1/2017, Volume 28, Issue 1, pp. 389 - 398
In a 2-year randomized, placebo-controlled study of 665 Japanese patients with primary osteoporosis, once-yearly administration of zoledronic acid (5 mg...